Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin

J Am Acad Dermatol. 2013 May;68(5):875-6. doi: 10.1016/j.jaad.2012.11.038.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents / therapeutic use
  • Blind Loop Syndrome / drug therapy*
  • Blind Loop Syndrome / epidemiology*
  • Female
  • Humans
  • Male
  • Pilot Projects
  • Prevalence
  • Rifamycins / therapeutic use*
  • Rifaximin
  • Rosacea / drug therapy*
  • Rosacea / epidemiology*
  • Treatment Outcome

Substances

  • Anti-Infective Agents
  • Rifamycins
  • Rifaximin